Pharmaceutical Research & Development

Our Drug Pipeline

Our drug research and development pipeline

Our product pipeline reflects our commitment to developing innovative products that help diagnose or treat gastrointestinal disorders. Salix focuses on innovative gastrointestinal products and investigating currently marketed products for new indications. This page features information on the compounds currently in our pipeline. Information on this page is current as of 07/02/2014.


Program Indication Clinical Phases
PHASE 2  PHASE 3
NDA/BLA
Under Review
Methylnaltrexone Bromide
MDP (Multi-Dose Pen)
Opioid induced constipation (OIC) in advanced illness  
Methylnaltrexone Bromide SC*
(Subcutaneous Injection)
OIC in chronic non-cancer pain
Methylnaltrexone Bromide
(Oral Formulation)
OIC in chronic non-cancer pain  
Rifaximin
for the treatment of IBS-D
(TARGET 3 - retreatment of
IBS-D)
Irritable bowel syndrome with diarrhea  
Rifaximin DR
(Delayed-Release)
Crohn's disease
 
Rifaximin SSD
(Soluble Solid Dispersion)
Prevention of complications with early decompensated liver cirrhosis  
Budesonide Foam Ulcerative proctitis or proctosigmoiditis
Investigational Bowel Purgative Bowel prep for preparation of colonoscopy and other abdominal procedures In development
Lumacan Assist in endoscopic detection of precancerous and cancerous lesions in the colon In development
Ruconest Acute angioedema attacks in patients with hereditary angioedema (HAE)
SAN-300 Rheumatoid Arthritis  
*Most recent development update summarized in the press release dated June 2014.
Most recent development update summarized in the press release dated July 2014.

SWB 13/22-3

Check out our latest Press Releases and News